润都股份：硫酸羟氯喹化学原料药上市申请获批

Company Update - RunDu Pharmaceutical (002923) received approval from the National Medical Products Administration (NMPA) for the marketing application of hydroxychloroquine sulfate as a chemical active pharmaceutical ingredient (API) [1] - Hydroxychloroquine sulfate is indicated for the treatment of rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases caused or exacerbated by sunlight [1] Product Indications - The approved API, hydroxychloroquine sulfate, has therapeutic applications in autoimmune and dermatological conditions [1] - Specific indications include rheumatoid arthritis, juvenile chronic arthritis, lupus erythematosus (both discoid and systemic), and sunlight-induced or exacerbated skin disorders [1]